A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.
about
Therapeutic limitations in tumor-specific CD8+ memory T cell engraftmentMelanoma Peptide Vaccines.High resolution human leukocyte antigen (HLA) class I and class II allele typing in Mexican mestizo women with sporadic breast cancer: case-control study.Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors.CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity.Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.Tumor antigen cross-presentation and the dendritic cell: where it all begins?Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression.Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens.Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia.Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.CD4 T cells and their role in antitumor immune responses.Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine.
P2860
Q24794258-4F88D926-86EC-426F-AF15-B19F95B43630Q30305778-AE2C0880-449C-4D48-A7AD-8F580D93746BQ33406039-970B64DC-2D63-4CFF-B913-ECF8C0FB9E79Q33944674-9A5ED0CB-CA1F-4897-BE37-D51C55969DF5Q34025520-DB4466EC-9811-4D0E-A33D-F7E87AA48C29Q34110762-BC89D4B2-E130-4A62-BF78-BBD676B1F3C7Q34210664-A8E4197A-C276-4CBD-BAB0-12CD17A918C3Q36004284-ABB00DCE-E03C-4026-A8A2-B096CC0FB0CBQ36081450-5979EDAA-ED0E-453F-9943-0EA3904B9357Q36367205-9599F3AF-F358-4103-8B0E-8F938653C0F2Q36370664-3E89C3DE-A2E6-492C-9115-2B7EB1DEC60DQ36375095-D1117BE6-3B74-450F-8945-03F6E3C6AE1EQ36794745-8EF9CF15-D522-4071-8F8D-5D859B97C515Q39312652-99C7C280-62BC-48D3-A58E-02FA2F549C87Q41812728-011E00B8-514B-4997-B6BD-E62601E795A6Q45862586-8167B165-C0EA-43D7-A252-06E464F8388F
P2860
A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
A tumor escape variant that ha ...... no longer serves as a target.
@ast
A tumor escape variant that ha ...... no longer serves as a target.
@en
type
label
A tumor escape variant that ha ...... no longer serves as a target.
@ast
A tumor escape variant that ha ...... no longer serves as a target.
@en
prefLabel
A tumor escape variant that ha ...... no longer serves as a target.
@ast
A tumor escape variant that ha ...... no longer serves as a target.
@en
P2093
P2860
P356
P1476
A tumor escape variant that ha ...... no longer serves as a target.
@en
P2093
P2860
P304
P356
10.1084/JEM.178.3.933
P407
P577
1993-09-01T00:00:00Z